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Research A human functional protein interaction network 
and its application to cancer data analysis
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Functional protein interaction network A high-quality human functional protein inter- action network is constructed. Its utility is dem- onstrated in the identification of cancer  candidate genes.
Abstract
Background: One challenge facing biologists is to tease out useful information from massive data sets for further 
analysis. A pathway-based analysis may shed light by projecting candidate genes onto protein functional relationship 
networks. We are building such a pathway-based analysis system.
Results: We have constructed a protein functional interaction network by extending curated pathways with non-
curated sources of information, including protein-protein interactions, gene coexpression, protein domain interaction, 
Gene Ontology (GO) annotations and text-mined protein interactions, which cover close to 50% of the human 
proteome. By applying this network to two glioblastoma multiforme (GBM) data sets and projecting cancer candidate 
genes onto the network, we found that the majority of GBM candidate genes form a cluster and are closer than 
expected by chance, and the majority of GBM samples have sequence-altered genes in two network modules, one 
mainly comprising genes whose products are localized in the cytoplasm and plasma membrane, and another 
comprising gene products in the nucleus. Both modules are highly enriched in known oncogenes, tumor suppressors 
and genes involved in signal transduction. Similar network patterns were also found in breast, colorectal and 
pancreatic cancers.
Conclusions: We have built a highly reliable functional interaction network upon expert-curated pathways and 
applied this network to the analysis of two genome-wide GBM and several other cancer data sets. The network 
patterns revealed from our results suggest common mechanisms in the cancer biology. Our system should provide a 
foundation for a network or pathway-based analysis platform for cancer and other diseases.
Background
High-throughput functional experiments, including
genetic linkage/association studies, examinations of copy
n u m b e r  v a r i a n t s  i n  s o m a t i c  a n d  g e r m l i n e  c e l l s ,  a n d
microarray expression experiments, typically generate
multiple candidate genes, ranging from a handful to sev-
eral thousands. These data sets are noisy and contain
false positives in addition to genes that are truly involved
in the biological process under study. An unsolved chal-
lenge is how to understand the functional significance of
multi-gene data sets, extract true positive candidate
genes, and tease out functional relationships among these
genes with confidence for use in further experimental
analysis.
Using biological pathways to interpret high-throughput 
data
One way to approach the above problem is to analyze the
data from the perspective of biological pathways [1,2]. A
pathway is a set of biochemical events that drives a cellu-
lar process. For example, the transforming growth factor
beta (TGFβ) pathway consists of a ligand receptor bind-
ing event that initiates a series of protein-protein interac-
tion (PPI), protein degradation, protein phosphorylation,
and protein-DNA binding events that transmit a regula-
tory signal and regulate proliferation, differentiation and
migration [3]. In cancer, the TGFβ signaling network
functions in complex ways to both suppress early tumor
growth and promote late stage progression [4]. Some
breast cancers [5-9] are thought to arise in part when
components of the TGFβ pathway are deleted, thereby
freeing the tissue from growth inhibition. The same type
of cancer can arise via several different routes [2]. For
example, tumors from two different patients might have
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deleted different components of the TGFβ pathway.
Although the two tumors both share the loss of TGFβ
growth inhibition, they may not share defects in a com-
mon gene or gene sets. However, a pathway-based analy-
sis will resolve this confusing finding and point towards
the etiology of the disease. By projecting the list of
mutated, amplified or deleted genes onto biological path-
ways, one will find that a statistically unlikely subset of
otherwise unrelated genes are closely clustered in 'reac-
tion space'. Pathway-based analysis can thus provide
important insights into the biology underlying disease
etiology. One striking example of this approach is the
finding of the 'exclusivity principle' in cancer: only one
gene is generally mutated in one pathway in any single
tumor [1].
Recently, several large-scale genome-wide screening
projects have revealed common core signaling pathways
in the etiology or progression of several cancer types [10-
14], indicating the relevance of pathway-based analysis
for the understanding of large scale disease data sets.
Pathway-based analysis accomplishes at least two things:
it marks the genes associated with the disease or other
phenotype and separates them from innocent bystanders
caught in the general instability of the malignant genome
or other false positive hits [15]; and it identifies the bio-
logical pathways affected by the genes [16]. The latter
outcome also places the high-throughput analysis results
in an intellectual framework that can be more easily com-
prehended by the researcher. It connects his results to
prior work from the literature, and allows him to propose
hypotheses that can be tested by further experimental
work.
Resources for pathway analysis
Pathway-based hypothesis generation has been the sub-
ject of great interest over the past few years [17]. It is the
basis for several popular data analysis systems, including
GOMiner [18,19], Gene Set Enrichment Analysis [20],
Eu.Gene Analyzer [21], and several commercial tools (for
example, Ingenuity Systems [22]).
Reactome [23] is an expert-curated, highly reliable
knowledgebase of human biological pathways. Pathways
in Reactome are described as a series of molecular events
that transform one or more input physical entities into
one or more output entities in catalyzed or regulated
ways by other entities. Entities include small molecules,
proteins, complexes, post-translationally modified pro-
teins, and nucleic acid sequences. Each physical entity,
whether it be a small molecule, a protein or a nucleic acid,
is assigned a unique accession number and associated
with a stable online database. This connects curated data
in Reactome with online repositories of genome-scale
data such as UniProt [24] and EntrezGenes [25], and
makes it possible to unambiguously associate a position
on the genome with a component of a pathway. A com-
putable data model and highly reliable data sets make
Reactome an ideal platform for a pathway-based data
analysis system. However, since all data in Reactome is
expert-curated and peer-reviewed to ensure high quality,
the usage of Reactome as a platform for high-throughput
data analysis suffers from a low coverage of human pro-
teins. As of release 29 (June 2009), Reactome contains
4,181 human proteins, roughly 20% of total SwissProt
proteins. Other curated pathway databases, including
KEGG [26], Panther Pathways [27], and INOH [28], offer
similarly low coverage of the genome.
In contrast to pathway databases, collections of pair-
wise relationships among proteins and genes offer much
higher coverage. These include data sets of PPIs and gene
co-expression derived from multiple high-throughput
techniques such as yeast two-hybrid techniques, mass
spectrometry pull down experiments, and DNA microar-
rays. These kinds of data sets are readily available from
many public databases. For example, PPIs can be down-
loaded from BioGrid [29], the Database of Interacting
Proteins [30], the Human Protein Reference Database
(HPRD) [31], I2D [32], IntACT [33], and MINT [34], and
expression data sets from the Stanford Microarray Data-
base [35] and the Gene Expression Omnibus [36]. Protein
or gene networks based on these pairwise relationships
have been widely used in cancer and other disease data
analysis with promising results [37-42].
Transforming pairwise interactions into probable 
functional interactions
A limitation of pairwise networks is that the presence of
an interaction between two genes or proteins does not
necessarily indicate a biologically functional relationship;
for example, two proteins may physically interact in a
yeast two-hybrid experiment without this signifying that
such an interaction forms a part of a biologically mean-
ingful pathway in the living organism. In addition, some
pairwise interaction data sets may have high false positive
rates [43,44], which contribute noise to the system, and
interfere with pathway-based analyses. For this reason,
groups that make pathway-based inferences on high-
throughput functional data sets inevitably draw on
curated pathway projects to cleanse their data and to
train their predictive models.
Our goal is to achieve the best of both worlds by com-
bining high-coverage, unreliable pairwise data sets with
low-coverage, highly reliable pathways to create a path-
way-informed data analysis system for high-throughput
data analysis. As the first step towards achieving this goal,
we have created a functional interaction (FI) network that
combines curated interactions from Reactome and other
pathway databases, with uncurated pairwise relationships
gleaned from physical PPIs in human and model organ-Wu et al. Genome Biology 2010, 11:R53
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isms, gene co-expression data, protein domain-domain
interactions, protein interactions generated from text
mining, and GO annotations. Our approach uses a naïve
Bayes classifier (NBC) to distinguish high-likelihood FIs
from non-functional pairwise relationships as well as out-
right false positives.
In this report, we describe the procedures to construct
this FI network (Figure 1), and apply this network to the
study of glioblastoma multiforme (GBM) and other can-
cer types by expanding a human curated GBM pathway
using our FIs, projecting cancer candidate genes onto the
FI network to reveal the patterns of the distribution of
these genes in the network, and utilizing network cluster-
ing results on cancer samples to search for common
mechanisms among many samples with different
sequence-altered genes. Finally, we introduce a web-
based user interface that gives researchers interactive
access to the derived FIs.
Results
Data sources used to predict protein functional 
interactions
We used the following six classes of data to predict pro-
tein FIs (Table 1): 1, human physical PPIs catalogued in
IntAct [45], HPRD [46], and BioGrid [47]; 2, human PPIs
projected from fly, worm and yeast in IntAct [45] based
on Ensembl Compara [48]; 3, human gene co-expression
derived from DNA microarray studies (two data sets
[49,50]); 4, shared GO biological process annotations
[51]; 5, protein domain-domain interactions from PFam
[52]; and 6, PPIs extracted from the biomedical literature
by the text-mining engine GeneWays [53].
Table 1 lists these data sources, the numbers of proteins
and interactions, and estimated coverage of the human
genome expressed as their coverage of the SwissProt pro-
tein database.
The coverage ranges from 7% (Worm PPIs) to 70% (GO
biological process sharing). It is notable that the coverage
of human physical PPIs from three public protein interac-
tion databases (IntAct, HPRD, and BioGrid) is close to
50%. Many interactions from IntAct were catalogued
from co-immunoprecipitation experiments combined
with mass spectrometry, and contain multiple proteins in
a single interaction record. An odds ratio analysis showed
that human PPIs based on all interaction records are
much less correlated to FIs (see below) extracted from
Reactome pathways than interactions containing four or
fewer interactors: 13.91 ± 0.52 versus 36.98 ± 9.17 (P-
value = 2.8 × 10-5 based on t-test). Therefore, we selected
interactions that contain only four or fewer interactors
from the IntAct database. We also tried to use GO molec-
ular functional annotations as one of the data sources.
The odds ratio of this data set was 2.99 ± 0.02, much
smaller than the GO biological process data set (11.85 ±
0.20). Our results show that this data set contributed little
to the prediction. One reason for this may be that the GO
molecular functional categories are usually broad and the
purpose of our NBC is to predict if two proteins may be
involved in the same specific reactions (see below).
Construction and training of a functional interaction 
classifier
Our goal was to create a network of protein functional
relationships that reflect functionally significant molecu-
lar events in cellular pathways. The majority of PPIs in
interaction databases are catalogued as physical interac-
tions, and there is rarely direct evidence in the interaction
databases that these interactions are involved in bio-
chemical events that occur in the living cell. Other pro-
tein pairwise relationships have similar issues. To
integrate pairwise relationships into a pathway context,
we built a scoring system based on the NBC algorithm, a
simple machine learning technique [54], to score the
probability that a protein pairwise relationship reflects a
functional pathway event.
F o r  o u r  N BC,  w e  u s ed  n i n e  f e a t u r e s  as  l i s t e d  u n d e r
'Data source' in Table 1: 1, whether there is a reported PPI
between the human proteins; 2, whether there is a
reported PPI between the fly (Drosophila melanogaster)
orthologs of the two human proteins; 3, whether there is
a reported PPI between the worm (Caenorhabditis ele-
Figure 1 Overview of procedures used to construct the function-
al interaction network. See text for details. BP, biological process.
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gans) orthologs of the two human proteins; 4, whether
there is a reported PPI between the yeast (Saccharomyces
cerevesiae) orthologs of the two human proteins; 5,
whether there is a domain-domain interaction between
the human proteins; 6 and 7, whether the genes encoding
the two proteins are co-expressed in expression microar-
rays based on two independent DNA array data sets; 8,
whether the GO biological process annotations for
human proteins are shared; and 9, whether there is a text-
mined interaction between the human proteins.
An NBC must be trained using positive and negative
training data sets in order to determine the proper
weighting of different combinations of features. We
developed training sets from the curated information in
Reactome, relying in part on an independent analysis that
reported Reactome as a highly accurate data set for PPI
prediction [55].
An issue in using PPIs and other pairwise relationships
in a pathway context is that the data models used by path-
way databases are much richer than a simple binary rela-
tionship. A pathway database describes pathways in
terms of proteins, small molecules and cellular compart-
ments that are related by biochemical reactions that have
inputs, outputs, catalysts, cofactors and other regulatory
molecules. To develop the training sets from Reactome
pathways for NBCs, we established a relationship called
'functional interaction' using the following definition: a
functional interaction is one in which two proteins are
involved in the same biochemical reaction as an input,
catalyst, activator, or inhibitor, or as two members of the
same protein complex.
It is important to note that in Reactome a 'reaction' is a
general term used to describe any discrete event in a bio-
logical process, including biochemical reactions, binding
interactions, macromolecule complex assembly, trans-
port reactions, conformational changes, and post-transla-
tional modifications [23]. We treat two members of the
same protein complex as functionally interacting with
each other because the activity of the complex as a whole
is presumably functionally dependent on the presence of
all of its subunits.
Based on the above definition, we extracted 74,869 FIs
from Reactome, and used these FIs to create a positive
training set for the NBC. After filtering out FIs that did
not have at least one feature derived from the data
sources in Table 1, the positive data set comprised 45,079
FIs.
Creating a good negative training set is more difficult
than creating a positive set due to the incompleteness of
our knowledge of protein interactions [56]: just because
two proteins are not known to interact does not mean
t ha t  t his does not  in  fact  oc cu r .  R esear c h gr oups  ha ve
addressed this problem using a variety of approaches,
including choosing protein pairs from different disjunct
cell compartments [57], or random pairs from all proteins
[58]. For our NBC training, we followed the method in
Zhang et al. [58] using random pairs selected from pro-
teins in the filtered Reactome FI set.
Choosing an appropriate prior probability or ratio
between the positive and negative data sets is important
for NBC training. We calculated the prior probability
based on the total number of proteins in the filtered FIs
from Reactome pathways, which was 5.7 × 10-3. To check
the effect of ratio between the sizes of the positive and
negative data sets, we test the NBC performance using a
ratio of either 10 or 100. NBCs trained with these two
ratios yielded similar true and false positive rates, which
indicated that our NBC is robust against the size of the
negative data set.
Table 1: Data sources used to predict protein functional interactions
Data source Proteins SwissProt proteins (coverage) Interactions Reference
Human PPIs 10,287 10,029 (49%) 53,743 [45-47]
Fly PPIs 13,383 4,088 (20%) 939,639 (26,346a)[ 4 5 ]
Worm PPIs 5,223 1,477 (7%) 122,192 (8,161a)[ 4 5 ]
Yeast PPIs 5,646 1,530 (8%) 1,900,980 (167,574a)[ 4 5 ]
Domain interaction 60,569 15,218 (75%) NA [52]
Lee's Gene Expression 8,250 7,647 (38%) 206,117 [49]
Prieto's Gene Expression 3,024 2,901 (14%) 13,441 [50]
GO BP sharing 14,197 14,197 (70%) NA [51]
PPIs from GeneWays 5,252 5,252(26%) 51,048 [53]
To calculate the coverage of SwissProt, we used 20,332, the total identifier number in SwissProt (UniProtKB/Swiss-Prot Release 56.9, 3 March 
2009), as the denominator. The numbers of interactions from three model organisms have been mapped to human proteins based on 
Ensembl Compara [48] (see text for details). aNumbers of PPIs in the original species. BP, biological process.Wu et al. Genome Biology 2010, 11:R53
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The performance of machine learning classifier systems
can be evaluated by cross-validation, or more stringently
by using an independent data set. We used FIs extracted
from pathways in other human curated pathway data-
bases as a testing data set to evaluate the performance of
our trained NBC. Figure 2 shows a receiver operating
characteristic curve that relates true positive rates to false
positive rates across a range of thresholds using this test-
ing data set. We chose a threshold score of 0.50, which
trades off a high specificity of 99.8% against a low sensi-
tivity of 20%. The low sensitivity may result, in part, from
high false negative rates existing in some of the data sets
we used for NBC, especially in PPIs [59].
At the threshold score (0.50), a protein pair must have
multiple types of FI evidence in order to be scored as a
true FI (Table S1 in Additional file 1). While most (97%)
of the predicted FIs have at least one PPI feature (Figure
S1 in Additional file 1), there are no predictions sup-
ported solely by human PPI data, and fewer than 3% are
supported solely by PPIs in human plus other species.
This greatly reduces the weight given to raw human PPI
features: the 44,819 human PPIs that went in to the classi-
fier as features resulted in fewer than 15,000 predicted
FIs, representing the removal of 68% of the raw PPIs.
Most (75%) of the predicted FIs are derived from GO bio-
logical process term sharing and protein domain interac-
tions in addition to PPIs.
As a check on the classifier's ability to enrich for FIs, we
compared the sharing of GO cellular component annota-
tions (which includes compartments such as 'nucleo-
plasm') among raw human PPIs to the sharing of these
annotations among predicted FIs. Since GO cellular com-
ponent annotations were not used as a feature during
NBC training, we reasoned that this assessment should
be independent. Among raw PPIs, 62.9% share GO cellu-
lar component terms annotated for both proteins
involved in the interaction. In contrast, 96.2% of the pre-
dicted FIs share this type of GO term (P-value < 2.2 × 10-
16), suggesting a substantial enrichment in true FIs rela-
tive to an interaction set derived from raw features alone.
Merging the NBC with pathway data to create an extended 
FI network
To construct an extended FI network with high protein
and gene coverage, we merged FIs predicted from our
trained NBC with annotated FIs extracted from five path-
way databases. The five pathway databases used were
Reactome [23], Panther [60], CellMap [61], NCI Pathway
Interaction Database [62], and KEGG [63] (Table 2).
To further increase the coverage of our network, we
imported interactions between human transcription fac-
tors and their targets from the TRED database [64].
TRED has two parts: one contains highly reliable, human
curated data from published literature and the other is
uncurated and comprises predictions based on several
computational algorithms. For our purposes, we used the
human curated part only to ensure the reliability of our FI
network, and treat these interactions as a part of the
pathway FIs in this report.
The extended FI network contains 10,956 proteins
(9,393 SwissProt accession numbers, splice isoforms not
counted) and 209,988 FIs (Table 3). It covers 46% of Swis-
sProt proteins.
The average connection degree (that is, the number of
interacting partners per protein) of the extended network
is 38, and the maximum degree is 593 for protein P32121
(ARRB2, Beta-arrestin-2). Most proteins in this network
are interconnected: 10,645 proteins are interconnected in
the largest connected graph component. The remaining
311 proteins reside in 124 connected graph components
of size 7 or smaller.
The FI network shows scale-free properties (data not
shown) as do other biological networks [65-68]. GO slim
annotation enrichment analysis results (not shown) show
that our network is enriched in proteins involved in signal
transduction, cell cycle and the central dogma. This
reflects the ascertainment bias of using Reactome as the
training set, as these pathways reflect high priorities for
Reactome curation.
Assessing the utility of functional interactions in the 
network
GBM is the most common type of brain tumor in humans
and also has the highest fatality rate. Recently, two data
sets from two independent high throughput screens for
somatic mutations involved in GBM have been released
[12,14]. In this section, we demonstrate that the interac-
tions from our network can be used to automatically
extend a hand-curated GBM pathway developed to sup-
port the analysis of one of these data sets [14]; the
extended GBM pathway captures more observed somatic
mutation events and can be used to generate testable bio-
logical hypotheses.
In preparation for analysis of The Cancer Genome
Atlas (TCGA) somatic mutation data set [14], a team of
bioinformaticians, molecular biologists and clinical
oncologists based at Memorial Sloan Kettering Cancer
Center and Dana-Farber Cancer Institute developed a
human-curated map of the molecular pathways involved
in GBM (Figures S7 and S8 in [14]; the original Cytoscape
file can be downloaded from [69]). Our network captures
the majority of proteins and interactions in this map: 96%
of proteins (70 of 73) and 69% of interactions (129 of 187).
The TCGA GBM screen captured 341 mutated genes,
including both point mutations and copy number varia-
tions (CNVs). Of these genes, 38 (11%) are part of the
original hand-curated GBM pathway, and 237 (70%) are
in the FI network. Of these genes in the FI network, 36Wu et al. Genome Biology 2010, 11:R53
http://genomebiology.com/2010/11/5/R53
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are in the original GBM pathway (15%), and in addition,
108 directly interact with at least one of the curated GBM
pathway genes, for a total of 42% of the somatic muta-
tions. This degree of interaction between somatically
mutated genes with the GBM pathway is far greater than
would be expected by chance (P-value = 1.3 × 10-23 by the
hypergeometric test), suggesting that the FI network pro-
vides an effective way to enrich the hand-curated GBM
pathway for additional genes involved in the disease.
Figure 2 Receiver operating characteristic curve for NBC trained with protein pairs extracted from Reactome pathways as the positive data 
set, and random pairs as the negative data set. This curve was created using an independent test data set generated from pathways imported 
from non-Reactome pathway databases. The positions for the cutoff values 0.25, 0.50 and 0.75 are marked from right to left in the inset. The area under 
the curve (AUC) for this receiver operating characteristic (ROC) curve is 0.93.
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We then added these potential proteins and interac-
tions to the GBM pathway map to extend it. In order to
do so, we chose proteins that were found to have one or
more somatic mutations in the GBM screen, and had
direct interactions with one or more of the proteins in the
hand-curated GBM pathway. In this way we were able to
extend the hand-curated pathway from 73 proteins and
187 interactions to 181 proteins and 768 interactions. A
total of 581 FIs were added between pathway compo-
nents and new mutated protein interactions (an increase
of 148% for proteins and 311% for FIs). Figure 3 shows the
original hand-curated map after extending it with pre-
dicted and curated FIs from the FI network involving
mutated genes. Interactions derived from curated path-
ways are represented as solid lines (with arrows for FIs
involved in catalysis and activation, and with a 'T' bar for
those involved in inhibition), while those predicted from
the NBC are shown as dotted lines. Many mutated pro-
teins interact with more than one pathway component.
For the purposes of readability, Figure 3 shows only pro-
teins that interact with one pathway component. A larger
diagram showing the fully extended map is available in
Figure S2 in Additional file 1.
A total of 23 of the FIs added to the GBM pathway in
Figure 3 were predicted by the NBC. To validate the accu-
racy of these predicted FIs, we searched the published lit-
erature for evidence supporting that two genes in the
predicted FIs are indeed functionally related. Table 4 lists
the literature references that support these interactions.
Out of 23 FIs, a total of 18 (78%) are supported by litera-
ture evidence for a functionally significant event. One FI
(ROS1-EGFR) has no literature evidence supporting it,
and the remaining four are confirmed physical interac-
tions but have no evidence of functional significance.
These results suggest that the predicted FIs are suffi-
ciently reliable to be safely integrated into known path-
ways for systematic analysis.
A detailed examination of the extended GBM pathway
can lead to hypotheses that connect the observed
sequence alteration in the TCGA data set to known bio-
logical pathways. For example, NUP50 is required for
degradation of CDKN1B protein [70]. Copy number dele-
tion in NUP50, which occurs in three TCGA GBM sam-
ples, may inhibit the degradation of CDKN1B and impact
the cell cycle process. For another example, tenascin-C
(TNC) protein is a ligand for epidermal growth factor
receptor (EGFR) [71]. Three re-sequenced GBM samples
have found TNC mutations, which may disturb the RTK/
RAS signaling pathway via its interaction with EGFR.
It needs to be pointed out that the directionality of the
interaction should be taken into account when using the
FI network to frame hypotheses. For example, two of the
pathway FIs around TP53, BAX-TP53 and GTSE1-TP53
were originally extracted from the KEGG human p53 sig-
Table 2: Pathway data sources in the functional interaction network
Data source Proteins SwissProt proteins (coverage) Interactions Reference
Reactome 4,490 3,863 (19%) 74,869 [23]
Panther 1,912 1,355 (7%) 33,425 [60]
CellMap 567 567 (3%) 1,195 [61]
NCI Nature 1,492 1,486 (7%) 10,845 [62]
NCI BioCarta 1,137 1,136 (6%) 6,695 [62]
KEGG 2,497 2,261 (11%) 13,934 [63]
TRED 1,167 1,166 (6%) 3,030 [64]
SwissProt coverages were calculated as described in Table 1. NCI Pathway Interaction Database has two divisions: batch-imported pathways 
from BioCarta [83] and pathways hand-curated by NCI Nature pathway curators. We represent these two divisions separately. TRED is a 
transcription factor/target database. We have imported the human curated part of transcription factor-target interactions from this database 
for our network.
Table 3: Protein identifiers and functional interactions in the extended FI network
Source type Proteins SwissProt proteins (coverage) Interaction
Pathways 6,316 5,496 (27%) 98,590
Predicted 8,345 7,546 (37%) 111,398
Total 10,956 9,393 (46%) 209,988
FIs listed in the pathways row include transcription factor-target interactions imported from the TRED database.Wu et al. Genome Biology 2010, 11:R53
http://genomebiology.com/2010/11/5/R53
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naling pathway [72]. The BAX and GTSE1 genes are tran-
scriptionally upregulated by TP53 protein. Though it is
not annotated in the original KEGG database, there is
evidence showing that GTSE1 protein can regulate TP53
protein's activity and localization [73]. However, there is
no evidence to suggest that the P53 pathway is affected by
BAX protein, a protein involved in apoptosis [74]. Hence,
mutations in BAX in a particular tumor do not support
an etiology involving P53 signaling, but instead might
p o i n t  t o  e v e n t s  d o w n s t r e a m  o f  P 5 3 .  T h e  s a m e  c a v e a t
applies to predicted FIs as well.
Clustering of GBM sequence-altered genes in the extended 
FI network
The previous section described how the FI network can
be used to enhance and extract novel hypotheses from a
previously created hand-curated disease pathway. In this
section, we illustrate how studies of distributions of
altered genes in the GBM samples in the FI network can
assist in genome-wide functional analysis when a preex-
isting disease pathway is unavailable.
Both the TCGA [14] and Parsons et al. [12] GBM stud-
ies identified recurrent patterns of somatic gene muta-
Figure 3 Overlay of predicted functional interactions onto a human curated GBM pathway from the TCGA data set. Many genes can interact 
with multiple pathway genes. In this diagram, only genes interacting with one pathway gene are shown to minimize diagram clutter. Newly added 
genes are colored in light blue, while original genes are colored in grey. Newly added FIs are in blue, while original interactions are in other colors. FIs 
extracted from pathways are shown as solid lines (for example, PHLPP-AKT1), while those predicted based on NBC are shown as dashed lines (for ex-
ample, KLF6-TP53). Extracted FIs involved in activation, expression regulation, or catalysis are shown with an arrowhead on the end of the line, while 
FIs involved in inhibition are shown with a 'T' bar. The original GBM pathway map in the Cytoscape format was downloaded from [69].Wu et al. Genome Biology 2010, 11:R53
http://genomebiology.com/2010/11/5/R53
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tions involving multiple classical signaling pathways
using a manual process of inspection and correlation to
the literature and a variety of pathway databases. Here,
we use network community analysis to automatically
identify network modules that contain genes and their
products that are involved in common processes.
The edge-betweenness algorithm [75] has been used to
find network modules in protein interaction networks
[76-78]. We applied this algorithm to search for FI net-
work modules for sequence-altered genes identified in
the two GBM data sets. Starting with the TCGA data set,
we collected 341 mutated and CNV genes from 91 GBM
samples that have been re-sequenced in that study. A
total of 237 of these genes (70%) were in the FI network.
Of these, 168 have mutual FIs and are interconnected. We
built a subnetwork around these 168 genes, applied the
edge-betweenness network clustering to it, and obtained
17 network modules, 6 of which were greater than size 4
(Figure 4).
The sizes of the first two modules (modules 0 and 1) are
63 and 50, respectively. The distribution study showed
that 76 out of 91 GBM samples have altered genes in both
module 0 and module 1 (84%, P-value < 1.0 × 10-4 from
permutation test). As a cross-validation test, we pro-
jected 22 samples from the discovery screen in the Par-
sons data set, which provided both somatic mutation and
CNV data, onto these network modules. The result
showed that 68% (15 out of 22) have altered genes in both
module 0 and module 1 from the TCGA data set (P-value
< 1.0 × 10-4). We also did a reciprocal test by applying the
Table 4: Literature references for predicted FIs added to human curated GBM pathway from the TCGA GBM data set
Pathway gene FI partner Reference Comment
CCNE1 FBXW7 [99] Turnover of CCNE1 protein is dependent on FBXW7 protein
CDK4 ASPM [100] Physical interaction: functional relationship is not clear
CDKN1A PIM1 [101] Pim-1 kinase dependent phosphorylation of p21Cip1/WAF1 (CDKN1A) influences 
subcellular localization of p21
CDKN1B NUP50 [70] NUP50 protein is required for degradation of CDKN1B protein, which is important in 
cell cycle regulation
E2F1 TRRAP [102] TRRAP is required as a cofactor for E2F transcriptional activation
EGFR ANXA1 [103] ANXA1 protein and other annexins are involved in degradation of EGFR protein
EGFR ROS1 This may be a false positive example
EGFR TNC [71] TNC protein is a ligand for EGFR
EP300 GLI1 [104] GLI1 is involved in a GLU1-p53 inhibitory loop
EP300 IQGAP1 [105] Physical interaction: functional relationship is not clear
EP300 PROX1 [106] Physical interaction: functional relationship is not clear
EP300 TCF12 [107] Form a functional complex in neurons
GRB2 SYP [108] SYP involvement in the RAS pathway has been reported some time ago
GRB2 TNK2 [109] TNK2 protein is a target of GRB2 protein
MSH6 PMS2 [110] PMS2 has been treated as a DNA repair gene
PDPK1 RPS6KA3 [111] Phosphoserine-mediated recruitment of PDPK1 to RPS6KA3 leads to coordinated 
phosphorylation and activation of PDPK1 and RPS6KA3
PRKCA ANXA7 [112] Calcium-dependent membrane fusion driven by annexin 7 can be potentiated by 
protein kinase C and guanosine triphosphate
SRC CD46 [113] CD46 is a substrate of SRC
SRC MAPK8IP2 [114] Though no direct evidence shows a functional relationship between these two 
genes, it is shown that an isoform of JIP (MAPK8IP2), JIP1, is regulated by Src family 
kinases
TP53 CYLD CYLD is a deubiquitinating enzyme. Several deubiquitinating enzyme have been 
shown to be involved in the p53 pathway; however, no evidence has been provided 
for CYLD in the p53 pathway
TP53 KLF4 [115] KLF4 is a direct suppressor of expression of TP53
TP53 KLF6 [116] Physical interaction: TP53 may enhance the function of KLF6
TP53 TOP1 [117] Activity of TOP1 may be modulated by P53Wu et al. Genome Biology 2010, 11:R53
http://genomebiology.com/2010/11/5/R53
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edge-betweenness clustering algorithm to a subnetwork
composed by altered genes from the Parsons data set, and
checking sample distributions from both GBM data sets
in the network modules. The results are similar to our
results in the TCGA data set: 77% (P-value = 0.0002) of
GBM samples in the Parsons data set, and 71% (P-value <
1.0 × 10-4) in the TCGA data set have altered genes in two
corresponding modules (Figure S3 in Additional file 1).
To see what biological features these two modules may
connote, we annotated these two modules using path-
ways and GO terms. GO cellular annotation enrichment
assay indicated that module 0 mainly corresponds to pro-
teins present in the cytoplasm and plasma membrane,
while module 1 mainly involves gene products present in
the nucleus. Many pathways can be assigned to these two
modules, but it is clear that module 0 is mainly related to
signaling transduction pathways while module 1 is related
to the cell cycle, DNA repair and pathways involved in
chromosome maintenance (Table S2 in Additional file 1).
T h e  f a c t  t h a t  m o s t  o f  t h e  G B M  s a m p l e s  h a v e  a l t e r e d
genes in both modules implies that these two major mod-
ules are acting cooperatively in establishing and/or main-
taining the GBM phenotype, and suggests that the
development of GBM cancers involve malfunctions in
both signaling transduction and cell-cycle regulation.
Our FI network is composed of a combination of
curated FIs and predicted FIs. To determine whether the
distribution of altered genes is robust, we checked the
above results against FI network modules composed of
FIs derived from curated FIs only. The results are similar
to those obtained using the integrated FI network except
that network modules 0 and 1 are smaller than the mod-
ules built with both predicted and pathway FIs (results
not shown). Figure 4 shows that many mutated genes are
brought into modules 0 and 1 based on predicted FIs
only, which are shown with dashed lines.
To further explore the distribution of mutations among
the network modules, we performed a hierarchical clus-
tering of the TCGA GBM samples based on the occur-
rence of altered genes in the modules (Figure 5). From
this clustering, we obtain five sample clusters of size 61,
Figure 4 Edge-betweenness network clustering results for the altered genes from the TCGA data set. Gene nodes in different clusters are dis-
played in different colors. GO cellular component annotation for clusters 0 and 1 are labeled in the diagram to show the major cellular localizations 
for genes in these two clusters. The node size is proportional to the number of samples bearing displayed altered genes.
Module 1: nucleus 
Module 0: cytoplasm, plasma membrane Wu et al. Genome Biology 2010, 11:R53
http://genomebiology.com/2010/11/5/R53
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13, 6, 9, and 2, respectively. Three types of samples were
used in the original TCGA screening (rightmost column
of Figure 5): recurrent samples (15, blue), secondary sam-
ples (4, red), and primary samples (72, green). Sample
cluster 0, which has a signature of mutations in both net-
work modules 0 and 1, is enriched in primary tumor sam-
ples (P-value = 0.055 from Fisher test). In contrast,
sample cluster 1, which has additional mutations involv-
ing network modules 8, 3, 9, 7 and others, is enriched in
samples from tumor recurrences and metastases (P-value
= 0.026). Indeed, all but one of the four metastatic sam-
ples can be found in sample cluster 1 (P-value = 0.0086).
In the original TCGA paper [14], seven of the recurrent
or metastatic samples were labeled as 'hyper-mutated'
because of their much higher rate of somatic mutation.
We found that except for one sample (TCGA-02-0099)
located in sample cluster 0, all of the other six samples are
in cluster 1 (P-value = 1.7 × 10-5). These results illustrate
how the mutated network modules can be used to differ-
entiate cancer samples.
Defining a GBM core cancer network
It is expected that multiple false positive ('passenger')
genes exist in the set of sequence-altered genes identified
from the GBM samples. It is also expected that true posi-
tive ('driver') GBM-related genes should occur more often
in GBM samples than by chance. We plotted the percent-
age of altered genes versus samples for both GBM data
sets (Figure 6), and compared this distribution against
what would be expected by random assignment of genes
to samples. There are two phases in the distribution of
altered genes across samples. In the first phase, involving
gene alterations occurring between two to five samples,
there is sharing of fewer altered genes than would be
expected by chance. In the second phase, involving genes
altered independently in six or more samples, there are
more altered genes shared among the samples than would
be expected by chance. This result can be explained if
there exist a minimum number of driver genes that must
be mutated in order to produce GBM, and that this 'GBM
core' tends to be recurrently mutated in independent
samples. Figure 6 also shows that the average shortest
path among shared genes from GBM samples decreases
versus sample numbers in contrast to random samples,
which implies that GBM candidate genes tend to be
closer in the FI network than by chance (see below).
To visualize sequence-altered genes and further define
the core set of genes in the GBM samples, we collected
genes altered in at least two samples to reduce the num-
ber of false positive GBM candidate genes, performed
hierarchical clustering among them to identify a set of
highly interconnected candidates, and then selected and
built subnetworks containing >70% of altered genes (Fig-
ure 7a, b) by adding the minimum number of linker genes
to form a fully connected subnetwork.
In the TCGA data set, 164 altered genes occurred in
two or more GBM samples, 98 (60%, P-value = 3.2 × 10-7)
of which were in the FI network. Of these, 71 are in the
GBM subnetwork (72%, P-value < 0.001 from permuta-
tion test). An average shortest distance calculation (Table
5) shows that genes in this cluster are linked together
much more tightly than would be expected by chance:
2.29 for subnetwork genes versus 3.83 for a similarly sized
random set of genes treated in the same way as the cancer
subnetwork. In the Parsons data set, 111 genes occur in
two or more GBM samples, 65 (59%, P-value = 8.4 × 10-5)
of which are in the FI network. Of these, 46 are in the
GBM cancer cluster (71%, P-value < 0.001 from permuta-
tion test). Similar to the TCGA data set, the average
shortest path among these genes is shorter than by
chance (2.76 versus 3.82, P-value < 0.001).
In the average shortest path calculation, a potentially
confounding factor in the TCGA data set is that 601
genes pre-selected for sequencing may be more tightly
interconnected than average. Indeed this is the case.
When we performed the permutation test using these
601 pre-selected genes, we obtained an average shortest
path of 2.40, which is shorter than the genome-wide aver-
age, but still longer than the length of 2.29 calculated for
the subnetwork formed by recurrently mutated genes (P-
value = 0.023; connection degrees have been considered
in permutation test (see below)). This consideration does
not apply to the Parsons set, which used an unbiased
resequencing approach.
In summary, results from both GBM data sets indicate
that more than 70% of the recurrently mutated genes are
more tightly interconnected than expected by chance,
and occupy a small corner of the large FI network space.
We found that the average connection degrees in the
GBM clusters are higher than the average connection
degree in the whole FI network (40 based on the biggest
connected graph component using gene names): 87 for
the TCGA cluster (P-value = 1.3 × 10-5 from t-test), and
60 for the Parsons cluster (P-value = 0.13). The result that
the average shortest path among altered genes in cancer
clusters is shorter than by chance may be an ascertain-
ment bias due to the higher connection degrees in the
cancer clusters resulting from the intensive study of sig-
nal transduction pathways, to which most GBM candi-
date genes belong. To determine whether the differences
in average shortest paths between the cancer clusters and
randomly selected genes are due entirely to the difference
in degree, we performed an additional permutation test
in which the genes picked were stratified by degree in
order to match the distribution of the cancer gene sets
(Table 6, Degree-based permutation column). This cor-
rection reduced, but did not eliminate, the differences inWu et al. Genome Biology 2010, 11:R53
http://genomebiology.com/2010/11/5/R53
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average shortest path between the cancer gene sets and
randomly selected genes, and the differences remained
statistically significant: both P-values < 0.001.
The reason why the average shortest paths for the
TCGA data set are smaller than the those calculated for
the Parsons set for both the cancer cluster and degree-
based permutation results is that re-sequenced genes in
the TCGA data set number 601 in total, which are pre-
selected and believed to be more cancer-related, while the
Parsons paper resequenced 20,661 protein coding genes.
Looking at the two GBM cancer subnetworks in more
detail, each subnetwork consists of GBM candidate genes
('cancer genes') plus the minimum number of interacting
genes necessary to interconnect them ('linker genes',
shown in red in Figures 7 and 8). The TCGA subnetwork
contains 77 genes, 5 of them linkers, while the Parsons
subnetwork contains 62 genes, 14 of them linkers. Since
Figure 5 Hierarchical clustering of GBM samples in the TCGA data set based on altered gene occurrences in the network modules identified 
by the edge-betweenness algorithm. The rows are samples, while the columns are 17 network modules. In the central heat map, red rectangles 
represent samples having altered genes in modules, while green rectangles represent samples having no altered genes in modules. The vertical blue 
dashed line shows the cutoff value we used to select sample clusters from the hierarchical clustering. The right-most column lists sample types: green 
for primary GBM samples ('No' in Table S1B in [14]), blue for recurrent ones ('Rec' in Table S1B in [14]), and red for secondary ones ('Sec' in Table S1B in 
[14]).
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Figure 6 Plots of altered genes versus samples. The horizontal axis is the sample numbers, and the left vertical axis is the percentage of altered 
genes occurring in samples related to total altered genes. The right vertical axis is the average shortest path among altered genes occurring in sam-
ples. (a) The TCGA data set. (b) The Parsons data set.
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many of our FIs were extracted from human curated
pathways, it is easy to superimpose pathways back to
these subnetworks to see what pathways are involved in
these cancer genes. Many pathways are statistically signif-
icantly hit by these genes. Figure 8 shows four pathways:
focal adhesion, signaling by platelet-derived growth fac-
tor (PDGF), p53, and cell cycle (false discovery rate <8.0 ×
10-4). As illustrated in Figure 8a, b, there are extensive
overlaps among, and cross-talk between, these pathways.
It is surprising that the two GBM studies identified a
relatively small number of GBM candidate genes in com-
mon: just 15 out of a total of 260 unique genes are shared
(6%) for all GBM candidate genes (13 out of a total of 150
unique genes (9%) for altered genes in the FI network).
Intriguingly, 12 out of 13 shared genes in the FI network
are present in the two cancer subnetworks we built inde-
pendently for the two data sets (Figures 7 and 8, shared
genes are in yellow; P-value = 0.0014 based on permuta-
tion test), suggesting that the GBM cancer clusters cap-
ture the common candidate genes. Interestingly, with the
exception of COL3A1, all the shared genes directly inter-
act with each other, suggesting that they form the core of
a GBM pathway, and that non-shared cancer genes are
extensions of the core network.
To further narrow down the list of candidate genes to
those that are likely to be drivers, we used the results
shown in Figure 6 to investigate candidate genes altered
in eight or more GBM samples in the TCGA data set, and
five or more samples in the Parsons data set. In the
TCGA data set, a total of 20 genes are altered in 8 or
more GBM samples. Of these 20 genes, 13 are in our FI
network, and 10 are displayed in Figure 7a: CDK2A,
CDK2B, CDK4, EGFR, MDM2, NF1, PTEN, RB1, PIK3R1,
and TP53. In the Parsons data set, 14 genes occur in 5 or
more samples, 10 are in the FI network, and 9 are dis-
played in Figure 7b: CDKN2A, CDKN2B, EGFR, IFNA1,
IFNA2, IFNA8, IFNE1, PTEN, and TP53. Out of these
genes, five are shared between these two data sets:
CDKN2A, CDKN2B, EGFR, PTEN, and TP53 (P-value =
5.8 × 10-13). The fact that these genes are altered in multi-
ple samples and shared in two studies further indicates
the existence of a GBM core network.
Application of the FI network to other cancer types
In this section, we test whether the network patterns
found in the GBM samples can also be found in other
cancer types. We applied our FI network to the genome-
wide data sets for breast [10], colorectal [10] and pancre-
atic cancers [11], and found similar patterns of clustering
of mutations into network modules.
In the breast and colorectal data sets, 18,191 genes
based on 20,857 transcripts were re-sequenced for 11
breast and 11 colorectal tumors during the discovery
phase. Mutated genes found in the discovery phase are
further validated with 24 additional samples of the same
tumor type. For network module analysis, we collected
mutated genes from the 11 discovery phase samples from
both breast and colorectal cancers, built interaction sub-
networks based on the FI network, clustered the subnet-
works using edge-betweenness, and compared the
resulting network modules to the distribution of patient
samples.
For breast cancer samples, 1,023 genes were mutated in
11 tumor samples. Of these, 524 genes are in our FI net-
work (51%). The edge-betweenness algorithm generated
33 clusters, of which 12 were of size 5 or greater. The sizes
of the first three modules are 55 (module 0), 49 (module
Figure 7 Subnetworks for GBM clusters. (a) The TCGA cluster. (b) 
The Parsons cluster. Shared GBM candidate genes are shown in yellow, 
non-shared candidate genes in aqua, and linker genes used to connect 
cancer genes in red. The node size is proportional to the number of 
samples bearing displayed altered genes. Other colors and symbols 
are as in Figure 2.
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1), and 26 (module 2) (Figure S4 in Additional file 1). The
sample distribution analysis showed that all 11 breast
samples had mutated genes in modules 0 and 1, and 9 out
11 breast tumor samples had mutated genes in modules
0, 1, and 2. A GO cellular component annotation enrich-
ment analysis showed that genes in module 0 are mainly
from the extracellular region, cytoplasm and the plasma
membrane, while genes in module 1 are found mainly in
the nucleoplasm, nucleus and nucleolus (Table S3 in
Additional file 1). Pathway annotation shows that genes
in module 0 are involved in integrin and focal adhesion
pathways, while genes in modules 1 and 2 are involved in
transcription, cell cycle and DNA repair (Table S3 in
Additional file 1).
For colorectal cancers, 766 genes were mutated in 11
tumor samples. Of these, 410 genes are in our FI network
(54%). We detected 31 modules from the edge-between-
ness algorithm, 8 of which were of size 5 or greater. Nine
out of 11 colorectal cancer samples had mutated genes
involving three network modules, modules 0, 1 and 4
(Figure S5 in Additional file 1). A GO cellular component
enrichment analysis (Table S4 in Additional file 1) dem-
onstrated that module 0 is enriched for plasma mem-
brane and cytosol, while module 1 is enriched in GO
terms describing the extracellular region, and module 4 is
enriched in terms for the nucleoplasm and nucleus. Com-
pared with breast cancer, module 0 in breast cancer has
been split into two modules in colorectal carcinoma.
Pathway annotation showed that genes in module 0 are
highly enriched in components of the endothelin and
Nerve Growth Factor (NGF) pathways, in contrast to
breast cancer and GBM, which show no such enrichment.
Genes in module 1 are involved in focal adhesion and
integrin pathways, while genes in module 4 are involved
in DNA repair (Table S4 in Additional file 1), all of which
are also enriched in breast cancer and GBM.
As with the two GBM data sets, we performed a hierar-
chical clustering analysis on genes mutated in at least two
or more samples. In this analysis, we used samples from
both the discovery and validation phases to increase the
sample numbers. Table S5 in Additional file 1 lists the
numbers of genes mutated in two or more samples,
mutated genes in the whole FI network, and mutated
genes in the clusters from hierarchical clustering; these
numbers indicate that most of the mutated genes are
clustered together in the FI network, as was previously
observed with GBM candidate genes. Also similar to the
results from the GBM analysis, the majority of cancer
candidate genes in both breast and colorectal cancers are
closer t han would be e x pect ed by chanc e (T a ble S6 in
Additional file 1). Figures S6 and S7 in Additional file 1
show these clusters with their pathway annotations. As
with GBM, many cancer-related pathways are signifi-
cantly enriched in these clusters.
We performed a similar network module and hierarchi-
cal clustering analysis on a pancreatic data set [11]. Our
results show that similar network patterns can be found
in pancreatic cancers (Tables S5, S6, and S7, and Figures
S8 and S9 in Additional file 1). We noted that 75% (P-
value = 0.38) of pancreatic samples (18 out of 24 samples)
have mutated genes in module 0 (nucleus and cytosol)
and module 1 (extracellular region), and 71% (P-value =
0.24) of samples (17 samples) have mutated genes in
Table 5: Clustering of GBM-related altered genes occurring in two or more samples in the FI network
Data set Cancer genes Genes in FI network (%) Genes in cluster Percentage of genes in cluster (P-value via
random permutation)
TCGA 164 98 (60%) 71 72% (<0.001)
Parsons 111 65 (59%) 46 71% (<0.001)
The numbers in the 'Cancer genes' column are for altered genes in two or more samples from the TCGA and Parsons data sets. Genes were 
collected using both somatic mutations and CNVs.
Table 6: Average shortest distance for GBM clusters
Data set Cancer genes Random permutation (P-value) Degree-based permutation (P-value)
TCGA 2.29 3.83 (< 0.001) 2.86 (<0.001)
Parsons 2.76 3.82 (< 0.001) 3.32 (<0.001)
The values in the 'Cancer genes' column are from the cancer clusters, while those in the two permutation columns are from permutation tests. 
Random permutation is done via randomly picking up the same number of genes from the biggest connected graph component as for the 
cancer genes, and degree-based permutation is done by picking up genes from different bins based on the degree distributions of cancer 
genes. The gene bins are dynamically generated based on the sorted list of degrees from the cancer genes.Wu et al. Genome Biology 2010, 11:R53
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module 0 and module 2 (plasma and integral to mem-
brane) (Figure S8 in Additional file 1).
As in the GBM analysis, we used permutation testing to
assess whether more of the breast, colorectal, or pancre-
atic cancer samples had mutations involving these mod-
ules than would be expected by chance. However, due to
the small number of samples available and the relatively
large number of mutations per specimen (32 to 49 altered
genes per specimen in the breast, colorectal and pancre-
atic sets, versus 22 per specimen in GBM), we failed to
demonstrate statistically significant overrepresentation of
specimens with mutated genes in these modules.
In conclusion, we found that most samples from breast,
colorectal or pancreatic cancers have sequence-altered
genes involving multiple modules localized in different
cellular localizations, and that most cancer candidate
genes in the FI network are closer than would be
expected by chance. The results are broadly similar to
those seen with GBM, but there are many intriguing dif-
ferences as well in the identity of the pathways involved.
Software tools for accessing the functional interactions
To make our FI data sets available to general researchers,
we developed a web-based application. This application
was built upon the current Reactome SkyPainter using
Google Web Toolkit (GWT) and is available at [79]. Fig-
ure 9 is a screenshot of the application when first
launched. At the top of the application is a Google-map
style view of all reactions manually curated for Reactome;
at the bottom is a hierarchical tree of all pathways, orga-
nized by biological process.
To find FIs, users can upload lists of UniProt accession
numbers or gene names for proteins or genes of interest.
The application will then highlight pathways involving
FIs with the proteins or genes of interest in both the reac-
tion map and the pathway hierarchy. When the user
selects a reaction that has been 'hit', a dialog appears that
provides detailed information on the relationship
between the reaction, its components, and FIs involving
those components (Figure 10a). The user can also select a
hit pathway in the hierarchical tree to bring up a pathway
diagram to show pathway components and its FIs (Figure
10b).
The entire set of FIs can be downloaded as a MySQL
database dump (Additional file 2) or in tab-delimited files
(Additional file 3) from this web application. There is no
restriction on their use or redistribution beyond citing
the source of the information.
Discussion
Increasingly, human diseases and other traits are being
probed by genome-wide screens. For example, several
recent papers [10-14] describe genome-wide screening
efforts to identify somatic mutations in several cancer
types. Placing such lists of genes or proteins into a path-
way context can yield information on the relationships
among these genes and has the potential to generate
hypotheses about the mechanism(s) linking these genes
to phenotypes.
Reliable pathway databases are essential for such an
analysis, but because of the effort needed to curate path-
ways is so human-intensive, even the largest pathway
database has a SwissProt coverage of under 20% (Table 2).
In this report, we describe how we have integrated sev-
eral large-scale experimental data sets to build and train a
machine-learning system that identifies potential 'func-
tional interactions' among pairs of human proteins. We
have combined the FIs predicted by this classifier with
the curated pathways from Reactome and other pathway
Figure 8 Subnetworks with pathways annotated for GBM clus-
ters. Many pathways are hit by GBM candidate genes. Only four of 
them are labeled for two GBM clusters in this diagram to simplify the 
diagram. Colors and symbols are as in Figure 6.
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databases to create an extended database of FIs that cov-
ers nearly 50% of the human proteome. Our literature
search for a small set of predicted FIs around a human
curated GBM pathway [14] shows that our prediction has
an accuracy around 78% (Table 4).
An essential step in building this extended FI network
was the construction of a naïve Bayes classifier to predict
FIs from a combination of physical PPI data and other
noisy sources of information.
NBC is a simple, robust method that is usually the first
to be tried in machine learning techniques. NBCs can fre-
quently yield better results than more sophisticated tech-
niques [80]. One requirement for a successful NBC is that
the features used in the classifier be independent. In our
NBC, we used human physical PPIs, protein-protein
int erologs fr om yeast, worm, and fly , two independen t
gene co-expression data sets, protein domain interac-
tions, GO biological process annotations and PPIs gener-
ated from text mining. Human PPIs, protein interactions
from other species, and gene-expression data sets were
generated experimentally, and meet the requirement for
independence. Many of the GO annotations and protein
domain interactions are based on sequence similarities
among proteins in different species. Hence, there is a
potential dependency among these two data types and
protein-protein interologs from yeast, worm and fly since
they all rely on the same phylogenetic trees. Many human
protein interactions in interaction databases we used
(IntAct, BioGrid, and HPRD) are human curated from
the literature. This literature may be used by the text min-
ing technique to generate PPIs. But we feel both effects
are likely to be small.
Many computational methods have been developed to
generate biological pathways and networks based on
DNA microarray or other similar data sets from scratch
with promising results [81]. Most recently, Vaske et al.
[82] developed a factor-graph-based method to expand
known pathways using array data sets generated from
perturbation experiments. Here we propose a new
approach to expand a known human curated pathway by
Figure 9 Front page of the web application for predicted functional interactions.Wu et al. Genome Biology 2010, 11:R53
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using FIs, with the example of the human curated GBM
pathway. Compared to the computational approach, our
method provides direct supporting evidence for
expanded FIs from curated pathways (for curated FIs)
and high reliability from multiple data sources (for pre-
dicted FIs). W e are in the process of developing a soft-
ware tool so human curators can make use of these FIs to
expand known pathways for expedited curating.
By applying our FI network to two independent GBM
data sets from whole-genome screening projects, we are
struck by the finding that most genes with recurrent
mutations (>70%; Table 6) co-cluster into a small corner
of huge FI space. These clusters are highly enriched in
classical signaling pathways as well as the cell cycle, in
agreement with pathway analyses performed by the origi-
nal authors of the studies. We are also able to identify
extensive crosstalk among the pathways, which indicates
the complexities in tumorigenesis. Furthermore, we show
how the FI network can reveal overlaps - and possibly
common mechanisms - between the two GBM studies.
This suggests a scenario in which the two cancer whole-
genome screening projects are sampling from a common
core cancer pathway that can be revealed by FI network
analysis.
Our result that most cancer candidate genes are clus-
tered together is similar to what was reported by Cui et
al.  [83] based on a much smaller signaling interaction
network generated from BioCarta [84] and CellMap [61],
Figure 10 Views of predicted functional interactions. (a) FIs in a reaction diagram. (b) FIs in a pathway diagram.
(a)
(b)Wu et al. Genome Biology 2010, 11:R53
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a small subset of our imported pathway databases. The
reason why most cancer genes cluster closely together is
still under investigation. The connection degree contrib-
utes to such clustering. However, the degree alone still
cannot interpret the clustering based on our degree-
based permutation test. We suspect that the major factor
that governs the clustering is from FIs among cancer
genes. A subset of cancer genes may form a small graph
component via these FIs in the huge FI network. Such a
small graph component may be used as a core to pull
other cancer genes together to form a bigger cluster.
Lin et al. [85] investigated network patterns for breast
and colorectal cancers using a similar but smaller data set
[86], and predicted that over half of the mutated proteins
(59 out of 83) in breast cancers participate in an interac-
tion cluster, but only a very small percentage of mutated
proteins in colorectal cancers form an interaction cluster,
which contains 12 proteins. We used different network
analysis approaches based on a larger and more reliable
FI network. Our results uncovered network modules that
have been mutated in the majority of cancer samples and
show that most recurrently mutated genes form a net-
work cluster that is more interconnected than would be
expected by chance in both breast and colorectal cancers.
The results from multiple cancer types imply that the pat-
terns revealed in our study might be common in all can-
cer types.
Multiple sources of evidence show that tumorigenesis
in human is a multi-step process and that genomes of
tumors have sequence alterations at multiple sites [1].
Pathway analysis indicates that many pathways are
mutated in cancer samples [2]. A striking finding from
our study is that, for all cancer types examined so far,
most samples have mutations involving a small number
of discrete network modules. One of these modules typi-
cally corresponds to cell cycle regulation, DNA repair,
and other nucleus-based processes, while another corre-
sponds to signal transduction events in the plasma mem-
brane and cytoplasm. This result suggests that the
transformation from normal cells to malignant cells
requires functional mutations in both nuclear and cyto-
plasm/plasma membrane-based pathways. However, our
work also suggests that different cancer types have differ-
ent network modules. A detailed network module based
comparison analysis is likely to reveal different specific
mechanisms in different cancer types.
A major motivation for this work was the desire to inte-
grate information from multiple pathway databases in
order to reduce the fragmentation of knowledge stored in
these useful resources. Even with common data models
such as BioPAX [87], this is not easy to accomplish due to
different focus of interests among the pathway databases,
and different standard operating procedures, which allow
the same series of biological reactions to be described
quite differently from one database to the next. By reduc-
ing the pathway databases into a series of pairwise FIs,
however, we have been able to merge five of the major
pathway databases into a single uniform data model,
although much information about the distinct roles of
each protein has been lost during the process. Much of
our current and future effort will be devoted to develop-
ing methods to map the FIs back to their original pathway
contexts in order to find causal and directional relation-
ships among the proteins.
Conclusions
We have built a FI network that covers close to half of
human gene products. This functional network, which
interconnects with the curated pathways available from
Reactome and other human curated pathway databases,
forms the foundation for a pathway-based data analysis
system for high-throughput data analysis. We have
applied this system to the analysis of two genome-wide
GBM data sets and data sets from other cancer types and
revealed common network patterns in cancer related
genes and samples, suggesting that there exists a core net-
work in GBM tumorigenesis.
Materials and methods
Importing data from non-Reactome pathway databases
Data from four non-Reactome human-curated pathway
databases were imported into the Reactome database (28
March 2009 release). These four databases are: Panther
[27], CellMap [61], NCI Pathway Interaction Database
[62], and KEGG [26]. To store these imported data into
the Reactome database, the original Reactome schema
was extended by adding one new class, Interaction, as a
subclass to Event, and a new attribute, dataSource, to the
top-most class DatabaseObject. The latter is used to track
the original data sources of imported instances. The data
formats used for importing were: BioPAX [87] for Cell-
Map (released June 2006) and NCI Pathway Interaction
Database (released March 2009), SBML [88] with Cell-
Designer additions for Panther (version 2.5, August
2008), and KGML for KEGG (released on March 8 2009).
After importing, all data from Reactome and the four
external databases were maintained in a database, which
was also used to store PPI data (see below). We have also
imported human transcription factor and target interac-
tions from the TRED database [64]. There are two types
of data in the TRED database: human curated data from
the published literature and predictions based on compu-
tational methods. Only the human data were imported to
ensure high quality. Panther uses protein families gener-
ated from hidden Markov models for pathway annota-
tions [60]. We only imported human UniProt proteins
that could be mapped to pathway components reliably
based on evidence codes used in the mapping file.Wu et al. Genome Biology 2010, 11:R53
http://genomebiology.com/2010/11/5/R53
Page 20 of 23
Importing protein-protein interaction datasets
Human PPIs were extracted from three PPI databases:
BioGrid [29] (release 2.0.50, February 2009), HPRD [31]
(released August 2007) and IntAct [33] (released March
2009). Data dumps in PSI-MI version 2.5 format from
these three databases were processed by an in-house Java
PSI-MI parser, converted into the extended Reactome
data format, and stored in the extended Reactome data-
base. An odds ratio analysis was used to check the corre-
lation between a PPI or other pairwise data set and FIs
extracted from Reactome pathways. The control groups
were generated from random pairs by using proteins
from the Reactome FIs. The reported odds ratio values in
the results section were based on ten permutations.
PPIs in S. cerevisiae, C. elegans and D. melanogaster PPI
data sets were downloaded from IntAct (released March
2009). Ensembl Compara [48] was used to map non-
human proteins onto putative human orthologs.
Other data sets for naïve Bayes classifier
The protein domain-domain interaction data set was
downloaded from pFam [52] (release 23.0, July 2008).
Two microarray co-expression data sets were used in
the NBC: one downloaded from [89], which was com-
piled from 60 data sets that contained a total of about
4,000 microarrays [49], and another generated by Prieto
et al. [50].
Protein GO annotations were downloaded from [90]
(gene_association.goa_human, released March 2009). A
PPI data set generated from a text-mining technique was
kindly provided by Rzhetsky et al. [53].
Training of naïve Bayes classifier
We used a NBC to score protein-protein pairwise rela-
tionships. These pairwise relationships were extracted
from nine data sources described above and used as fea-
tures to train the NBC. We used a closed-world hypothe-
sis [91] to assign values to a protein pair: if there was a
pairwise relationship between the two proteins in the
data set, we used true, otherwise false.
To integrate protein-protein pairwise relationships into
the pathway context, we extracted pairwise relationships
from reactions and complexes annotated in pathways by
defining a FI as an interaction in which two proteins are
involved in the same reaction as input, catalyst, activator
and/or inhibitor, or as components in a complex. To train
the NBC, we extracted a positive data set from Reactome
using this definition, and filtered out pairs that do not
have any feature. We generated a negative training set
using random pairs from proteins in the positive data set.
Clustering of cancer genes in the functional interaction 
network
Two human GBM data sets [12,14] were used in our can-
cer data analysis. For sequence-altered genes in GBM, we
chose mutated genes and CNV genes for each sample.
Many genes exist in CNV chromosome fragments. For
our study, we chose those genes that have been labeled
'Genes with gene expression correlated with copy num-
ber' in the TCGA data set (Table S3 in [14]) or 'Candidate
target' and 'Other genes' in the Parsons data set (Tables
S5 and S6 in [12]). Note that CNV genes in the TCGA
data set have been pre-filtered based on gene expression
data sets, while CNV genes in the Parsons have not since
only SAGE expression data are available, which were not
used for filtering because of their lower sensitivity for
under-regulated genes. To get CNV genes for each sam-
ple in the TCGA data set, we used a file, TCGA-GBM-
RAE-genemap-n216-20080510-dscrt.txt, downloaded
from [92], which lists CNVs for individual samples [93].
For edge-betweenness network clustering [75], we
lumped all sequence-altered genes from samples
together, searched FIs among these genes, and con-
structed a subnetwork based on these interactions. A Java
graph library, Jung2 [94], was used for edge-betweenness
network clustering. Hierarchically clustering of TCGA
GBM samples was done using the hclust method in R [95]
based on the complete linkage method with the binary
distance between binary vectors generated for each GBM
sample according to occurrence of altered genes in net-
work modules identified by the edge-betweenness algo-
rithm. The heat map from hclust was drawn using the R
package heatplus [96].
To search for GBM cancer clusters, we collected
sequence-altered genes occurring in two or more samples
(GBM candidate genes), calculated pairwise shortest
paths among genes in the FI network, hierarchically clus-
tered them based on the average linkage method, and
then selected a cluster containing more than 70% altered
genes. To estimate P-value for GBM cancer clusters, we
did a 1,000-fold permutation test by randomly choosing
the same numbers of genes from the biggest connected
graph component as the GBM candidate genes to subject
to the same hierarchical procedures for the candidate
genes.
To construct a subnetwork spanning a set of genes, we
implemented a search algorithm guided by the hierarchi-
cal clustering results based on shortest path between two
clusters in order to keep the number of linking genes to a
minimum. To calculate the P-value for the average short-
est distance for cancer clusters, we performed a 1,000-
fold permutation test by randomly selecting the same
numbers of genes from the biggest connected graph com-
ponent. To check if the connection degree is a con-
founder to clustering of cancer genes, we repeated this
analysis after dynamically generating gene bins based on
the sorted list of degrees in the cancer genes, and then
randomly choosing genes from these bins in the same dis-
tribution as the cancer genes.Wu et al. Genome Biology 2010, 11:R53
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For other cancer types, we used Table S3 from [10] for
somatic mutated genes in breast and colorectal cancers,
and Tables S3, S4, and S5 from [11] for somatic mutated
and CNV genes in pancreatic cancers.
All network diagrams were drawn with Cytoscape [97].
The functional enrichment analyses for pathways and GO
annotations were based on binomial test. False discovery
rates were calculated based on 1,000 permutations on all
genes in the FI network.
Enhanced experimental SkyPainter
Skypainter is a web application implemented in the Reac-
tome web site for gene or protein over-representation
analysis [23]. We augmented the function of the original
Skypainter by adding predicted FI data. The enhanced
Skypainter was implemented using the Google web tool-
kit [98].
Additional material
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